Abstract: A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient.

Abstract: Stable aqueous spore-containing chemical formulations having a low to medium viscosity profile are provided. The formulations comprise at least one spore in a mixture of water and at least one water miscible solvent, optionally at least one surfactant, optionally at least one stabilizer such as a metal salt, optionally at least one biocide, optionally at least one buffer, and optionally at least one chemical insecticide or fungicide or a mixture thereof. The formulations are particularly suitable as a seed coating and foliar spray. Methods of preparation as well as methods of treating a plant are also provided.

Abstract: The present invention provides pathogen-inactivated red blood cell compositions.

Abstract: The invention relates to a method for separating blood, to a separation container and to a system, wherein different blood fractions—erythrocytes (64), buffy coat (65) and blood plasma (66)—are obtained, wherein blood is introduced into a separation container (1) and is then centrifuged into different superimposed, fluidically connected sections of the separation container, specifically a top section (4) for receiving the blood plasma (66), a middle section (3) for receiving the buffy coat, and a bottom section (2) for receiving the erythrocytes (64). The aim of the invention is to optimize the extraction of buffy coat. Said aim is achieved by means of the method and the separation container, wherein the optimization is geared to obtaining a defined phase boundary, and by means of the system, wherein the optimization is geared to achieving freedom from contamination from the time the blood enters the separation container and obtaining an easy-to-handle freezer container for cryopreservation.

Abstract: The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a GSK3 inhibitor and a TGF-? inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates. Useful cell culture kits for producing such dopaminergic cells are also described herein, as are methods of using such cells for stem cell therapy.

Abstract: The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient. The method may comprise the steps of causing migration of leukocytes separated from a healthy human or cells of an established cell line with a chemotactic factor contained in a sample such as body fluid or blood of the patient to be tested or a sample stimulated with the agent that may be allergenic to the patient and analyzing the cell kinetics such as migration velocity, migration distance, and migration direction.

Abstract: The invention provides an assay-ready frozen eukaryotic cell (stored frozen) in a composition that includes a cryopreservative and an inhibitor of xanthine oxidase, a kit containing a plurality of the assay-ready frozen eukaryotic cell, and a method of preparation thereof to minimize the variability in the performance of the cell, particularly in terms of undesirable intra- and inter-assay variability.

Abstract: A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analog thereof; noradrenaline; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenaline; and noradrenaline are present in concentrations of each about 0.010 ?M to 0.100 ?M, for example in a ratio of 1:1:1.

Abstract: A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells.

Abstract: A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFR?, CD31, CD235a, CD73, CD43, and CD41a.

Abstract: A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.

Abstract: The present invention provides a method for producing adult oligodendrocyte progenitor cells from proliferative oligodendrocyte progenitor cells, and a pharmaceutical composition having for an active ingredient thereof adult OPC produced according to that method. The method for producing adult OPC of the present invention is characterized by inducing proliferating OPC to differentiate into adult OPC by culturing in the presence of a ligand of a thyroid hormone receptor or retinoic acid receptor in a low oxygen environment. The present invention further provides adult OPC produced according to the production method of the present invention, and a pharmaceutical composition having these adult OPC as an active ingredient thereof.

Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.

Abstract: A method of preventing chicken white diarrhea and coccidiosis by providing a population of chickens an effective amount of a non-antibiotic feed, without feeding the chickens antibiotics. The feed includes a feed base and a feed additive. The feed additive can include various ingredients, including selenium and superoxide dismutase (SOD).

Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.

Abstract: The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder.

Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can be used for selecting cells that express ALDH. The detectable substrate can have a fluorescent moiety that has an excitation wavelength, an emission wavelength, or both, that does not overlap with the excitation wavelength, emission wavelength, or both, of green fluorescent protein.

Abstract: The present invention generally relates to the use of synergistic amounts of Bacillus thuringiensis subsp. kurstaki and chlorantraniliprole for the control of Diamondback Moth, Beet Armyworm, Sugarcane Borer, Soybean Looper and Corn Earworm. Specifically, the synergistic ratio of Bacillus thuringiensis subsp. kurstaki to chlorantraniliprole is from about 1:0.001 to about 1:3.

Abstract: The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation.

Abstract: Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture.